NervGen Pharma to Present at 2nd Spinal Cord Injury Investor Symposium

June 20, 2024- NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech firm focused on pioneering treatments for nervous system damage, revealed that its President & CEO, Mr. Mike Kelly, will deliver a corporate update at the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The event is organized by Lineage Cell Therapeutics, Inc., the California Institute for Regenerative Medicine, and the Christopher & Dana Reeve Foundation. Mr. Kelly's presentation is scheduled for June 27, 2024, at 2:00 p.m. PDT during the Clinical Spinal Cord Injury Session.

The 2nd SCIIS will take place in-person on June 26 and 27, 2024, at the Duane Roth Auditorium within the Sanford Consortium for Regenerative Medicine in La Jolla, CA.

NervGen Pharma Corp. is a biotechnology company at the clinical stage, committed to developing groundbreaking treatments that enable the nervous system to repair itself following injury or disease. The company's leading drug candidate, NVG-291, is currently being tested in a Phase 1b/2a clinical trial targeting spinal cord injury as its initial indication.

NervGen holds worldwide rights to NVG-291, an innovative therapeutic peptide that targets mechanisms obstructing nervous system repair. This drug is derived from the intracellular wedge domain of receptor type protein tyrosine phosphatase sigma (PTPσ). NVG-291-R, a rodent version of NVG-291, has demonstrated the ability to promote nervous system repair and functional recovery in animal models dealing with spinal cord injury, both acute and chronic, as well as peripheral nerve injury, multiple sclerosis, and stroke. These benefits occur through enhanced plasticity, axonal regeneration, and remyelination. The U.S. Food and Drug Administration has granted NVG-291 Fast Track Designation for spinal cord injury.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!